The IPKat has just enjoyed purr-using the fourth and most recent edition of Philip Grubb's book Patents for Chemicals, Pharmaceuticals and Biotechnology (published by Oxford University Press and available in hardback for £59). Coming five years after the well-regarded third edition, this book is current to May 2004. Accordingly in its text one can still see the impending clouds of the Community patent which have since been dispelled. One of the nice things about this book is that it has kept its sense of proportion. Rather than seek to cram its pages with reference to large numbers of ephemeral decisions from the courts and granting authorities, the author -- a consultant to pharma giant Novartis -- sensibly focuses on the overall shape and structure of his subject, homing in on the main principles and neatly emphasising their centrality. It is easy for a reader, on completing this work, to feel that he is a lot more knowledgeable than he probably is, since its pages have a somewhat empowering and confidence-building effect -- but the author, in keeping with good patent practice, does not allow himself to make any claims that exceed the substance of his invention (even the book's subtitle, "Fundamentals of Global Law, Practice and Strategy", contains no overstatement: the book is exactly that). Incidentally, at £59 for a hardback book of over 500 pages which is devoid of the usual statutory appendices, this work can scarcely be bettered in terms of punch per penny.

Philip Grubb (right) tells Khama Rogo (Chairman of the Kenya
Medical Association) how to do neat tricks with pharma patents

Visit Philip Grubb's website here
LOVELY GRUBB LOVELY GRUBB Reviewed by Jeremy on Monday, February 21, 2005 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here:

Powered by Blogger.